CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The US Food and Drug Administration (FDA) approval – the first for mesothelioma in 16 years and the second FDA-approved systemic therapy for mesothelioma – was based on a randomized, open-label trial, of 605 patients. The endpoint was to determine if the nivolumab-ipilimumab combo improved overall survival compared to chemotherapy.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
